“Explore 1% of medical entrepreneurial star species”
Text | Dun Yuting
A new force in medicine across the cycle
In 2020, menacing new crown pneumonia will sweep the world. In this war “epidemic”, from the laboratory to the front line of fighting the epidemic, we have seen the speed of China’s scientific research achievements in pathogen detection, disease epidemic monitoring and early warning, rapid screening, clinical diagnosis and treatment, and new drug / vaccine research and development. ; And the positive value of online consultation and consultation business, 2B medical services, etc.
However, the new crown epidemic has also disrupted the industry rhythm. The cash flow of most institutions has been affected to varying degrees, and it has also magnified the anxiety and concerns of all sectors about the lack of overall medical resources. In the long run, the epidemic is likely to accelerate the improvement of the infectious disease prevention and treatment system and the hierarchical diagnosis and treatment system, thereby accelerating the construction of large-scale medical projects. It is foreseeable that there will be a greater amount of capital and R & D investment entering in the future, which will be beneficial to the further acceleration of the development of the medium and long-term medical and health industry.
In addition to the epidemic, the medical and health industry has frequently ushered in policy dividends, from the “Outline of the” Healthy China 2030 “Plan” to the “Opinions of the General Office of the State Council on Promoting the Development of” Internet + Medical Health “” Last year’s government work report of the two sessions of the Communist Party of China “all escorted” the medical and health industry. Because of this, the industry’s innovation and entrepreneurship is still high, and it has been the focus of capital to become a leader across the economic cycle.
In terms of single financing amount, the average single financing amount of the industry from 2014 to 2017 has changed less by about 40 million yuan. In 2018, the average single financing amount increased significantly to 95 million yuan, which is In the past few years, it has increased by about 130%. From the perspective of financing rounds, more than 60% of the financing rounds of medical startups are still in the B round and before the B round, and the industry as a whole is still in an early stage of development.
It can be seen that there is never a lack of innovation in the field of health care. There are always opportunities, but also challenges.
As a special race circuit related to life, the medical and health industry has always faced higher entry barriers and longer cycles, whether it is research and development of innovative technologies, product production, or subsequent market sales.Each link determines whether the pharmaceutical innovation project can “take off” smoothly. In addition, the industry also faces problems such as a shortage of talents in the pharmaceutical research and development field, rising clinical costs, and serious homogenization issues.
The track winds up. If companies can’t achieve innovation, strengthen the talent base and make good grain reserves, it will be difficult to achieve sustainable development and be invincible in this battle with time, and miss out. Golden window of development. In other words, the meeting of innovation and opportunity at the right time requires the help of the platform and the support of industry resources.
Platform grafting innovation and opportunity
To this end, it will host the “New Medical Force” project call for entrepreneurial “Star” species competition to find those medical startup projects with the most innovation, growth and value; and co-operate with start-ups, traditional Market participants such as enterprises, local governments, institutional investors, and individual users help them achieve efficient linking of resources and capital through four core rights: industry expert guidance, investment agency matching, brand exposure, and university guidance. And the development of health science and technology achievements and innovation and entrepreneurship projects in the health and medical industry.
The “New Medicine Power” competition is divided into three major tracks: “Medical services”, “Medical technology”, and “Smart medical treatment” Selection is conducted in the road. It is worth mentioning that this competition has also received the support of many partners, such as the incubator brand created by the Ningbo Research Institute of Fudan University, which can create space, the well-known Internet medical platform Lilac Garden, and the new education technology service provider Goose.
In addition, considering the obvious regional advantages of the Yangtze River Delta, this competition will be held in East China in the form of sub-regions. The specific flow is as follows:
-
From the end of March to mid-May, conduct omni-channel recruitment, involving government recommendation, incubator recommendation, investment institution recommendation, joint office space recommendation, university recommendation, author recommendation, and independent registration, etc .;
-
After mid-May to the end of May, project selection was conducted. After preliminary screening by professional analysts and online review by review instructors, the list of 10 “star species” participating in the finals was determined;
-
On May 31, pre-match training was conducted, including dimensions such as industry expert guidance, capital perspective guidance, brand management and roadshow training;
-
On June 10th, the final roadshow will be launched, and 10 “star species” will start the final competition;
-
After that, continue to import resources to the excellent team, Covering investor docking, big coffee 1v1 docking, corporate services and E-club membership.
The “Star” Species Contest for Entrepreneurs runs throughout the year in the form of two seasons, “Spring Contest” and “Winter Contest”, and is a new attempt to connect entrepreneurs, investment institutions and traditional large companies. The “New Power of Medicine” project is the highlight of the “Spring Race”.
Previously, the first “Star” Species Contest “Winter Race” has been successfully held-officially launched on September 23, 2019, involving “Industrial Internet”, “Enterprise Services”, “New Technology” The four major tracks of “Consumer Consumption” have recruited nearly a thousand projects over 66 days and selected the 12 most popular “star species” from investors, providing them with government docking, access to well-known investment institutions, and targeted arrangements. Services such as docking of large company counterparts, well-known companies such as Huawei Cloud and Alibaba have participated in them and received high praise from the industry.
The “Star” Species Contest “Spring Race”-“New Medicine” is about to kick off, with the goal of recruiting round B and pre-B round medical industry startups. At that time, the head of investment agency partners will be invited as the offline judges to review the participating projects, the authors will be organized to use the reporting standard as the review standard to ensure a professional preliminary selection mechanism, and star entrepreneurial leaders will be invited as offline guests to evaluate the project from the perspective of entrepreneurship.
At the inflection point of the epidemic, let’s gather together to start the “Star” Species Contest, jointly explore innovative business opportunities, write a new chapter in corporate growth, and bring more information about medical and health practitioners after the epidemic. Thinking of long-term industry development opportunities.
The competition for the competition is in progress, please click the official website link to register for the competition: https://star.36kr.com/star-2020-yl
Not enough
The “Innovation Consulting” WeChat public account is waiting for you.
Scan the QR code below, or search for “Innovation Consulting” (ID: Kr8-36Kr-Innovation) on WeChat, and innovation will not fall behind.
